Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Type 2 Diabetes: An Epidemic Among America's Youth
With the number of children suffering from type 2 diabetes growing at an alarming rate, physicians gathered Saturday to discuss strategies for prevention and treatment of the disease among children and adolescents at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress.
generic viagra online
Xeloda(R)-Oxaliplatin Combination (XELOX) Shown To Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer
Genentech, Inc. announced that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery. The data show those who participated in the study and took XELOX immediately after surgery lived longer without their cancer being detectable than those who took intravenous 5U/LV. No new adverse events related to Xeloda were observed in the study.
News of the day
Times Of Zambia/allAfrica.com Examines Maternal Mortality, Abortion
The Times of Zambia/allAfrica.com examines abortion in Zambia and efforts to reduce maternal mortality. "Unsafe abortions are one of the top five causes of maternal mortality in Zambia," writes the newspaper, which adds they are one factor keeping the country from meeting the U.N. Millennium Development Goal target of reducing maternal mortality.
Medical Devices

Hard To Treat Diseases (HTDS) Clinical Trial Update On Therapeutic Effects Of Combined Treatment With Ribavirin And Tiazofurin

Hard To Treat Diseases (HTDS) Chief Scientist with its Slavica BioChem subsidiary, Dr. Sanja Pekovic provided updates on recent clinical trials with animal subjects in regards to the use of Ribavirin And Tiazofurin for the potential treatment of Multiple Sclerosis (MS). Dr. Pekovic reported; "It is now well accepted that axonal injury begins at an early stage in MS, and likely accounts for clinical progression seen later in the disease course, suggesting that early, aggressive treatment is critical in order to suppress long-term disability progression. Researchers from IBISS group (a related research group) tested the effect of combined treatment with ribavirin (R) and tiazofurin (T) administrated during the effecter phase of disease. Dr. Pekovic added: "We are hopeful, that with additional funding, we will be able to continue along this promising path, and continue researching the potential applications of a combination of ribavirin and tiazofurin in the treatment of MS." Safe Harbor Statement Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision"s under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc"s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc"s control. In addition to those discussed in Hard To Treat Diseases Inc"s press releases, public filings, and statements by Hard To Treat Diseases Inc"s management, including, but not limited to, Hard To Treat Diseases Inc"s estimate of the sufficiency of its existing capital res, Hard To Treat Diseases Inc"s ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc"s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc"s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Hard to Treat Diseases


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009